(Q37773253)

22 August 2017

1 reference

title

New perspectives in cancer virotherapy: bringing the immune system into play (English)

1 reference

22 August 2017

2

Frédéric Tangy

1 reference

22 August 2017

Nicolas Boisgerault

1

1 reference

22 August 2017

Marc Gregoire

series ordinal

3

1 reference

22 August 2017

publication date

1 March 2010

1 reference

22 August 2017

1 reference

22 August 2017

volume

2

1 reference

22 August 2017

issue

2

1 reference

22 August 2017

page(s)

185-199

1 reference

The tumour microenvironment: a novel target for cancer therapy

22 August 2017

cites work

1 reference

RNA viruses as virotherapy agents

21 January 2018

1 reference

Newcastle disease virus therapy of human tumor xenografts: antitumor effects of local or systemic administration

21 January 2018

1 reference

Newcastle disease virus exerts oncolysis by both intrinsic and extrinsic caspase-dependent pathways of cell death

21 January 2018

1 reference

Phase 1 clinical experience using intravenous administration of PV701, an oncolytic Newcastle disease virus

21 January 2018

1 reference

A phase 1 clinical study of intravenous administration of PV701, an oncolytic virus, using two-step desensitization

21 January 2018

1 reference

An optimized clinical regimen for the oncolytic virus PV701.

21 January 2018

1 reference

Phase I/II trial of intravenous NDV-HUJ oncolytic virus in recurrent glioblastoma multiforme

21 January 2018

1 reference

Selective oncolytic effect of an attenuated Newcastle disease virus (NDV-HUJ) in lung tumors

21 January 2018

1 reference

Vesicular stomatitis virus as an oncolytic vector

21 January 2018

1 reference

Vesicular stomatitis virus: re-inventing the bullet

21 January 2018

1 reference

The RAS/Raf1/MEK/ERK signaling pathway facilitates VSV-mediated oncolysis: implication for the defective interferon response in cancer cells

21 January 2018

1 reference

Oncolytic activity of vesicular stomatitis virus is effective against tumors exhibiting aberrant p53, Ras, or myc function and involves the induction of apoptosis

21 January 2018

1 reference

Systemic vesicular stomatitis virus selectively destroys multifocal glioma and metastatic carcinoma in brain.

21 January 2018

1 reference

Antitumor and antimetastatic activities of vesicular stomatitis virus matrix protein in a murine model of breast cancer.

21 January 2018

1 reference

Measles virus receptors: SLAM and CD46.

21 January 2018

1 reference

Cancer resistance to complement-dependent cytotoxicity (CDC): Problem-oriented research and development

21 January 2018

1 reference

High CD46 receptor density determines preferential killing of tumor cells by oncolytic measles virus

21 January 2018

1 reference

Measles virus as an oncolytic vector platform

21 January 2018

1 reference

Oncolytic measles virus in cutaneous T-cell lymphomas mounts antitumor immune responses in vivo and targets interferon-resistant tumor cells

21 January 2018

1 reference

Endogenous inhibitors of the dsRNA-dependent eIF-2 alpha protein kinase PKR in normal and ras-transformed cells

21 January 2018

1 reference

Reovirus oncolysis of human breast cancer

21 January 2018

1 reference

Reovirus therapy of lymphoid malignancies

21 January 2018

1 reference

Oncolytic reovirus effectively targets breast cancer stem cells

21 January 2018

1 reference

Synergistic effects of oncolytic reovirus and cisplatin chemotherapy in murine malignant melanoma

21 January 2018

1 reference

Synergistic antitumor activity of oncolytic reovirus and chemotherapeutic agents in non-small cell lung cancer cells

21 January 2018

1 reference

A phase I study of intravenous oncolytic reovirus type 3 Dearing in patients with advanced cancer

21 January 2018

1 reference

Immune-mediated antitumor activity of reovirus is required for therapy and is independent of direct viral oncolysis and replication

21 January 2018

1 reference

Oncolytic treatment and cure of neuroblastoma by a novel attenuated poliovirus in a novel poliovirus-susceptible animal model

21 January 2018

1 reference

Oncolytic rat parvovirus H-1PV, a candidate for the treatment of human lymphoma: In vitro and in vivo studies

21 January 2018

1 reference

Non-engineered, naturally oncolytic herpes simplex virus HSV1 HF-10: applications for cancer gene therapy

21 January 2018

1 reference

Pilot study of oncolytic viral therapy using mutant herpes simplex virus (HF10) against recurrent metastatic breast cancer

21 January 2018

1 reference

Intratumoral injection of herpes simplex virus HF10 in recurrent head and neck squamous cell carcinoma

21 January 2018

1 reference

Measles as a potential oncolytic virus

21 January 2018

1 reference

Oncolytic viral therapies

21 January 2018

1 reference

Modified adenoviruses for cancer gene therapy

21 January 2018

1 reference

Engineering targeted viral vectors for gene therapy

21 January 2018

1 reference

Inhibition of human tumor growth in mice by an oncolytic herpes simplex virus designed to target solely HER-2-positive cells

21 January 2018

1 reference

In vivo retargeting of adenovirus type 5 to alphavbeta6 integrin results in reduced hepatotoxicity and improved tumor uptake following systemic delivery.

21 January 2018

1 reference

Tumor and vascular targeting of a novel oncolytic measles virus retargeted against the urokinase receptor

21 January 2018

1 reference

Prostate-specific membrane antigen retargeted measles virotherapy for the treatment of prostate cancer

21 January 2018

1 reference

From ONYX-015 to armed vaccinia viruses: the education and evolution of oncolytic virus development

21 January 2018

1 reference

Strategies for therapeutic targeting of the p53 pathway in cancer.

21 January 2018

1 reference

Late viral RNA export, rather than p53 inactivation, determines ONYX-015 tumor selectivity

21 January 2018

1 reference

Cellular genetic tools to control oncolytic adenoviruses for virotherapy of cancer

21 January 2018

1 reference

Survivin-responsive conditionally replicating adenovirus exhibits cancer-specific and efficient viral replication

21 January 2018

1 reference

Viral vectors for gene-directed enzyme prodrug therapy.

21 January 2018

1 reference

Engineered herpes simplex virus expressing bacterial cytosine deaminase for experimental therapy of brain tumors

21 January 2018

1 reference

Oncolytic virotherapy for ovarian carcinomatosis using a replication-selective vaccinia virus armed with a yeast cytosine deaminase gene

21 January 2018

1 reference

Treatment of radioresistant stem-like esophageal cancer cells by an apoptotic gene-armed, telomerase-specific oncolytic adenovirus

21 January 2018

1 reference

Potent antitumor efficacy of ST13 for colorectal cancer mediated by oncolytic adenovirus via mitochondrial apoptotic cell death

21 January 2018

1 reference

Oncolytic viruses: a novel form of immunotherapy

21 January 2018

1 reference

Reovirus activates human dendritic cells to promote innate antitumor immunity

21 January 2018

1 reference

Measles virus induces oncolysis of mesothelioma cells and allows dendritic cells to cross-prime tumor-specific CD8 response

21 January 2018

1 reference

High-mobility group box 1 (HMGB1) protein at the crossroads between innate and adaptive immunity

21 January 2018

1 reference

Recombinant Newcastle disease virus (NDV) with inserted gene coding for GM-CSF as a new vector for cancer immunogene therapy

21 January 2018

1 reference

Rational strain selection and engineering creates a broad-spectrum, systemically effective oncolytic poxvirus, JX-963

21 January 2018

1 reference

Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial

21 January 2018

1 reference

An oncolytic adenovirus expressing granulocyte macrophage colony-stimulating factor shows improved specificity and efficacy for treating human solid tumors

21 January 2018

1 reference

A Phase I study of KH901, a conditionally replicating granulocyte-macrophage colony-stimulating factor: armed oncolytic adenovirus for the treatment of head and neck cancers.

21 January 2018

1 reference

Genetically engineered Newcastle disease virus for malignant melanoma therapy

21 January 2018

1 reference

Interleukin-12 expression enhances vesicular stomatitis virus oncolytic therapy in murine squamous cell carcinoma

21 January 2018

1 reference

Triple combination of oncolytic herpes simplex virus-1 vectors armed with interleukin-12, interleukin-18, or soluble B7-1 results in enhanced antitumor efficacy

21 January 2018

1 reference

Oncolytic adenovirus expressing interleukin-18 induces significant antitumor effects against melanoma in mice through inhibition of angiogenesis

21 January 2018

1 reference

Potent antitumor effect of interleukin-24 gene in the survivin promoter and retinoblastoma double-regulated oncolytic adenovirus

21 January 2018

1 reference

Targeted cancer gene therapy using a hypoxia inducible factor dependent oncolytic adenovirus armed with interleukin-4

21 January 2018

1 reference

Myxoma virus expressing interleukin-15 fails to cause lethal myxomatosis in European rabbits.

21 January 2018

1 reference

Targeting interferon-alpha increases antitumor efficacy and reduces hepatotoxicity of E1A-mutated spread-enhanced oncolytic adenovirus

21 January 2018

1 reference

Adenovirus delivery provides extended interferon-alpha exposure and augments treatment of metastatic carcinoma

21 January 2018

1 reference

Adenovirus-mediated interferon alpha gene transfer induces regional direct cytotoxicity and possible systemic immunity against pancreatic cancer

21 January 2018

1 reference

Targeting the intratumoral dendritic cells by the oncolytic adenoviral vaccine expressing RANTES elicits potent antitumor immunity

21 January 2018

1 reference

Heat shock protein 70, released from heat-stressed tumor cells, initiates antitumor immunity by inducing tumor cell chemokine production and activating dendritic cells via TLR4 pathway

21 January 2018

1 reference

Heat shock proteins and immune system

21 January 2018

1 reference

Human heat shock protein 70 enhances tumor antigen presentation through complex formation and intracellular antigen delivery without innate immune signaling.

21 January 2018

1 reference

Calreticulin exposure dictates the immunogenicity of cancer cell death

21 January 2018

1 reference

Viral subversion of immunogenic cell death

21 January 2018

1 reference

Molecular identification of a danger signal that alerts the immune system to dying cells

21 January 2018

1 reference

HMGB1 signals through toll-like receptor (TLR) 4 and TLR2.

21 January 2018

1 reference

Toll-like receptors in inflammation, infection and cancer

21 January 2018

1 reference

Antitumoral immune response by recruitment and expansion of dendritic cells in tumors infected with telomerase-dependent oncolytic viruses.

21 January 2018

1 reference

Antiglioma immunological memory in response to conditional cytotoxic/immune-stimulatory gene therapy: humoral and cellular immunity lead to tumor regression

21 January 2018

1 reference

Arming parvoviruses with CpG motifs to improve their oncosuppressive capacity

21 January 2018

1 reference

Attraction and activation of dendritic cells at the site of tumor elicits potent antitumor immunity

21 January 2018

1 reference

Adenovirus-mediated CD40 ligand therapy induces tumor cell apoptosis and systemic immunity in the TRAMP-C2 mouse prostate cancer model.

21 January 2018

1 reference

Growth inhibition of human multiple myeloma cells by an oncolytic adenovirus carrying the CD40 ligand transgene

21 January 2018

1 reference

Antitumor activity of an oncolytic adenoviral-CD40 ligand (CD154) transgene construct in human breast cancer cells

21 January 2018

1 reference

Improved systemic delivery of oncolytic reovirus to established tumors using preconditioning with cyclophosphamide-mediated Treg modulation and interleukin-2

21 January 2018

1 reference

Effect of adenovirus-mediated heat shock protein expression and oncolysis in combination with low-dose cyclophosphamide treatment on antitumor immune responses

21 January 2018

1 reference

Cyclophosphamide facilitates antitumor efficacy against subcutaneous tumors following intravenous delivery of reovirus

21 January 2018

1 reference

Immunosuppression enhances oncolytic adenovirus replication and antitumor efficacy in the Syrian hamster model.

21 January 2018

1 reference

Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses

21 January 2018

1 reference

Mesenchymal stem cell carriers protect oncolytic measles viruses from antibody neutralization in an orthotopic ovarian cancer therapy model

21 January 2018

1 reference

Dendritic cells and T cells deliver oncolytic reovirus for tumour killing despite pre-existing anti-viral immunity

21 January 2018

1 reference

Cell carriers for oncolytic viruses: Fed Ex for cancer therapy

21 January 2018

1 reference

The case of oncolytic viruses versus the immune system: waiting on the judgment of Solomon

21 January 2018

1 reference

Replicative oncolytic herpes simplex viruses in combination cancer therapies

21 January 2018

1 reference

The emergence of combinatorial strategies in the development of RNA oncolytic virus therapies

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.2217/IMT.10.6

1 reference

release_jwatqb4uvnh3pegfsjlxuawfki

22 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/jwatqb4uvnh3pegfsjlxuawfki

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference